Cargando…

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules

BACKGROUND: Enzastaurin, an oral serine–threonine kinase inhibitor, was initially developed as an ATP-competitive selective inhibitor against protein kinase Cβ. However, the mechanism by which enzastaurin contributes to tumourigenesis remains unclear. METHODS: We analysed the anti-tumour effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimokawa, T, Seike, M, Soeno, C, Uesaka, H, Miyanaga, A, Mizutani, H, Kitamura, K, Minegishi, Y, Noro, R, Okano, T, Yoshimura, A, Gemma, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305973/ https://www.ncbi.nlm.nih.gov/pubmed/22333600 http://dx.doi.org/10.1038/bjc.2012.7

Ejemplares similares

Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules
por: Körner, A, et al.
Publicado: (2010)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
por: CAO, MENGRU, et al.
Publicado: (2012)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells
por: Strillacci, A, et al.
Publicado: (2006)

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
por: Imai, K, et al.
Publicado: (2011)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

PARVB overexpression increases cell migration capability and defines high risk for endophytic growth and metastasis in tongue squamous cell carcinoma
por: Eslami, A, et al.
Publicado: (2015)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells
por: Fontijn, D, et al.
Publicado: (2006)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
por: Jeon, T-Y, et al.
Publicado: (2010)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy
por: Koukourakis, M I, et al.
Publicado: (2014)

Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma
por: Nagata, M, et al.
Publicado: (2011)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2011)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines
por: Masi, A, et al.
Publicado: (2005)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
por: Caiazza, F, et al.
Publicado: (2015)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
por: Calcagno, A M, et al.
Publicado: (2008)

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer
por: Hsu, K-F, et al.
Publicado: (2015)

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
por: Fu, Yi-Peng, et al.
Publicado: (2016)

Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial–mesenchymal transition and poor overall survival
por: Kucia-Tran, Justyna A, et al.
Publicado: (2016)

Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1
por: de Groot, D J A, et al.
Publicado: (2007)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis
por: Natatsuka, Rie, et al.
Publicado: (2015)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour
por: Kölby, L, et al.
Publicado: (2005)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4np2l2807joj8ruo0dss888ok6